- Home
- DGNX vs IMCR Comparison
DGNX vs IMCR Comparison
Compare DGNX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- IMCR
- Stock Information
- Founded
- DGNX 2018
- IMCR 2008
- Country
- DGNX Hong Kong
- IMCR United Kingdom
- Employees
- DGNX N/A
- IMCR N/A
- Industry
- DGNX
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGNX
- IMCR Health Care
- Exchange
- DGNX NYSE
- IMCR Nasdaq
- Market Cap
- DGNX 1.2B
- IMCR 1.4B
- IPO Year
- DGNX 2025
- IMCR 2021
- Fundamental
- Price
- DGNX $54.13
- IMCR $29.80
- Analyst Decision
- DGNX
- IMCR Buy
- Analyst Count
- DGNX 0
- IMCR 12
- Target Price
- DGNX N/A
- IMCR $63.00
- AVG Volume (30 Days)
- DGNX 139.2K
- IMCR 219.1K
- Earning Date
- DGNX 01-01-0001
- IMCR 05-07-2025
- Dividend Yield
- DGNX N/A
- IMCR N/A
- EPS Growth
- DGNX N/A
- IMCR N/A
- EPS
- DGNX N/A
- IMCR N/A
- Revenue
- DGNX $1,177,066.00
- IMCR $310,202,000.00
- Revenue This Year
- DGNX N/A
- IMCR $18.97
- Revenue Next Year
- DGNX N/A
- IMCR $8.43
- P/E Ratio
- DGNX N/A
- IMCR N/A
- Revenue Growth
- DGNX N/A
- IMCR 24.37
- 52 Week Low
- DGNX $3.60
- IMCR $27.69
- 52 Week High
- DGNX $82.51
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- IMCR 48.80
- Support Level
- DGNX N/A
- IMCR $28.24
- Resistance Level
- DGNX N/A
- IMCR $31.44
- Average True Range (ATR)
- DGNX 0.00
- IMCR 1.59
- MACD
- DGNX 0.00
- IMCR 0.08
- Stochastic Oscillator
- DGNX 0.00
- IMCR 52.33
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.